Adaptimmune
15
1
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
53.3%
8 terminated/withdrawn out of 15 trials
38.5%
-48.0% vs industry average
0%
0 trials in Phase 3/4
140%
7 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Role: lead
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC
Role: lead
To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
Role: collaborator
AFPᶜ³³²T in Advanced HCC
Role: lead
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Role: lead
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Role: lead
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Role: lead
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
Role: lead
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
Role: lead
SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer
Role: lead
Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors
Role: lead
Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy
Role: collaborator
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Role: lead
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
Role: lead
CT Antigen TCR-Engineered T Cells for Myeloma
Role: lead
All 15 trials loaded